 Home > Active Ingredient News > Antitumor Therapy > Circulation: Which is the relative cardiovascular safety of GnRH antagonists and agonists?

Circulation: Which is the relative cardiovascular safety of GnRH antagonists and agonists?

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

food safety software

open source office

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Artery atherosclerotic heart vascular disease (ASCVD) prostate cancer patients died mainly non-cancer reasons

This is an international, multi-center, prospective, randomized, open-label clinical trial, recruiting prostate cancer patients with atherosclerotic cardiovascular disease, randomly (1:1) divided into two groups, receiving GnRH antagonism Intervention treatment with degarelix or GnRH agonist leuprolide for 12 months

GnRH antagonist degarelix GnRH agonist leuprolide Cardiovascular events Stroke

Incidence of the two main outcomes

As the enrollment was slower than expected and the main outcome events were less than expected, the recruitment was stopped early

Time to the main outcome of the two groups

It is understood that this trial (PRONOUNCE) is the first international randomized clinical trial that prospectively compares the cardiovascular safety of GnRH antagonists and GnRH agonists in prostate cancer patients

No difference in major adverse cardiovascular events between the degarelix group or leuprolide group was observed at 1 year Difference in major adverse cardiovascular events

Original source:

Renato D.

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.